Welcome to our dedicated page for PTC THERAPEUTICS SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PTC THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PTC THERAPEUTICS's regulatory disclosures and financial reporting.
PTCT submitted a Form 144 notice reporting the proposed sale of 24,613 shares of Common Stock in connection with a Stock Option Exercise dated 07/07/2026. The filing lists Fidelity Brokerage Services LLC as the selling broker and indicates cash as the method.
The filing also discloses recent sales by Neil G. Almstead: 23,749 shares on 06/22/2026, 5,323 shares on 06/24/2026, 20,960 shares on 06/25/2026, 8,130 shares on 06/26/2026, and 22,161 shares on 07/06/2026. The filing is a Rule 144 notice of resale transactions.
PTCT notice reports restricted/common shares sold under Rule 144 and a stock option exercise converted to common stock on 07/06/2026. The filing lists multiple dispositions by Neil G. Almstead in June 2026 with specific share counts and aggregate sale proceeds shown.
PTCT affiliate submitted a Form 144 reporting proposed sales of Common Stock by an affiliate and several recent dispositions. The filing lists a planned sale tied to a Stock Option Exercise on 07/06/2026 and multiple sales by Mark Boulding on 04/06/2026, 05/08/2026, 05/15/2026, and 06/17/2026.
The excerpt shows specific share counts and dollar amounts for those transactions, including 2,265 shares for $157,282.96 on 04/06/2026 and 10,522 shares for $827,607.27 on 06/17/2026.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported an options exercise and pre-planned share sale. He exercised stock options to acquire 8,130 shares of common stock at an exercise price of $38.10 per share and sold 8,130 shares in open-market transactions at weighted average prices in the mid-$85 range, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he holds 60,137 shares of PTC Therapeutics common stock directly and 2,737 shares indirectly through his spouse.
PTC Therapeutics, Inc. chief technical operations officer Neil Gregory Almstead reported a series of option exercises and share sales in PTCT common stock. On June 24–25, 2026, he exercised stock options for a total of 26,283 shares at exercise prices including $38.10 and $39.42 per share.
Over the same two days, he sold 26,283 shares of common stock in open-market transactions at prices generally in the mid‑$80s, with individual sale prices such as $87.00 and weighted‑average prices around $85–$86 per share. Following these transactions, Almstead directly holds 60,137 shares of PTCT common stock.
The filing notes that these transactions were carried out under a written Rule 10b5-1 trading plan adopted on November 11, 2025, indicating they were pre‑scheduled rather than timed discretionarily.
PTCT affiliate submitted a Form 144 providing notice of a proposed sale of 8,130 shares of Common Stock via a stock option exercise dated 06/26/2026. The filing also lists multiple sales by Neil G. Almstead in the past three months, including 52,003, 23,749, 5,323, and 20,960 shares on the dates shown.
PTCT reported a Rule 144 notice showing the sale of 20,960 shares by Fidelity Brokerage Services LLC via a stock option exercise on 06/25/2026 for cash. The filing also lists earlier dispositions by Zheng Y. Almstead: 52,003 shares on 04/01/2026, 23,749 shares on 06/22/2026, and 5,323 shares on 06/24/2026, with disclosed proceeds for each sale. Shares outstanding are shown as 82,949,338 as of 06/25/2026.
PTC Therapeutics’ Chief Technical Operations Officer Neil Gregory Almstead reported an options exercise and matching share sales in Common Stock. He exercised stock options for 23,749 shares at $25.69 per share, then sold 23,749 shares in open-market transactions at weighted average prices of about $80.61 and $81.21 per share under a written Rule 10b5-1 trading plan adopted on November 11, 2025. He also reports 2,737 shares of Common Stock held indirectly through his spouse.
PTCT filing reports Rule 144 dispositions by an insider and a scheduled issuer exercise. The filing lists two past dispositions by Neil G. Almstead: 52,003 common shares on 04/01/2026 for $3,590,359.84 and 23,749 common shares on 06/22/2026 for $1,921,431.84. The notice also lists 5,323 common shares to be sold on 06/24/2026 in a Stock Option Exercise by the issuer for cash.
PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an exercise-and-sell stock transaction. She exercised options to acquire 19,686 shares of common stock at $25.69 per share and sold 19,686 shares in the open market at $75.56 per share on the same date. After these transactions, she directly holds 70,199 shares of common stock and 15,314 stock options as shown in the derivative table. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026.